Table of Contents
Metal-Based Drugs
Volume 2008 (2008), Article ID 576104, 6 pages
http://dx.doi.org/10.1155/2008/576104
Review Article

Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs

1Laboratorio de Biología Molecular, Subdirección de Investigación Básica, Instituto Nacional de Cancerológica, Avenida San Fernando 22, Tlalpan 14080, Mexico
2Genómica Funcional de Cáncer de Laboratorio, Instituto Nacional de Medicina Genomita, Mexico City 03020, Mexico

Received 12 July 2007; Accepted 18 December 2007

Academic Editor: Rafael Moreno-Sanchez

Copyright © 2008 Vilma Maldonado Lagunas and Jorge Meléndez-Zajgla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Peyrone, “Ueber die einwirkung des ammoniaks auf platinchlorür,” Annalen der Chemie und Pharmacie, vol. 51, no. 1, 1 pages, 1844. View at Publisher · View at Google Scholar
  2. A. Werner, “Beitrag zur konstitution anorganischer verbindungen,” Zeitschrift für anorganische Chemie, vol. 3, no. 1, 267 pages, 1893. View at Publisher · View at Google Scholar
  3. B. Rosenberg, L. Van Camp, and T. Krigas, “Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode,” Nature, vol. 205, no. 4972, 698 pages, 1965. View at Publisher · View at Google Scholar
  4. B. Rosenberg, “Platinum coordination complexes in cancer chemotherapy,” Naturwissenschaften, vol. 60, no. 9, 399 pages, 1973. View at Publisher · View at Google Scholar
  5. S. Ishida, J. Lee, D. J. Thiele, and I. Herskowitz, “Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, 14298 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  6. M. T. Kuo, H. H. W. Chen, I.-S. Song, N. Savaraj, and T. Ishikawa, “The roles of copper transporters in cisplatin resistance,” Cancer and Metastasis Reviews, vol. 26, no. 1, 71 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. G. Laurent, L. C. Erickson, N. A. Sharkey, and K. W. Kohn, “DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines,” Cancer Research, vol. 41, 3347 pages, 1981. View at Google Scholar
  8. K. Chválová, V. Brabec, and J. Kašpárková, “Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin,” Nucleic Acids Research, vol. 35, no. 6, 1812 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. L. Martelli, F. Di Mario, P. Botti, E. Ragazzi, M. Martelli, and L. Kelland, “Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status,” Biochemical Pharmacology, vol. 74, no. 1, 20 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. V. Brabec and J. Kasparkova, “Modifications of DNA by platinum complexes relation to resistance of tumors to platinum antitumor drugs,” Drug Resistance Updates, vol. 8, no. 3, 131 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. I. Husain, S. G. Chaney, and A. Sancar, “Repair of cis-platinum-DNA adducts by ABC excinuclease in vivo and in vitro,” Journal of Bacteriology, vol. 163, no. 3, 817 pages, 1985. View at Google Scholar
  12. T. Furuta, T. Ueda, G. Aune, A. Sarasin, K. H. Kraemer, and Y. Pommier, “Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells,” Cancer Research, vol. 62, no. 17, 4899 pages, 2002. View at Google Scholar
  13. V. Maldonado, J. Melendez, H. Gonzalez, and A. Ortega, “Internucleosomal DNA cleavage in HeLa cells exposed to cisplatin,” Biochemistry and Molecular Biology International, vol. 37, no. 4, 691 pages, 1995. View at Google Scholar
  14. Y. K. Kim, H. J. Kim, C. H. Kwon et al., “Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells,” Journal of Applied Toxicology, vol. 25, no. 5, 374 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. B. W. Zanke, K. Boudreau, E. Rubie et al., “The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat,” Current Biology, vol. 6, no. 5, 606 pages, 1996. View at Publisher · View at Google Scholar
  16. I. Sánchez-Pérez, M. Martínez-Gomariz, D. Williams, S. M. Keyse, and R. Perona, “CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin,” Oncogene, vol. 19, no. 45, 5142 pages, 2000. View at Google Scholar
  17. P. Bragado, A. Armesilla, A. Silva, and A. Porras, “Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation,” Apoptosis, vol. 12, no. 9, 1733 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. P. Pandey, J. Raingeaud, M. Kaneki et al., “Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms,” Journal of Biological Chemistry, vol. 271, no. 39, 23775 pages, 1996. View at Publisher · View at Google Scholar
  19. Y. Mitsuuchi, S. W. Johnson, M. Selvakumaran, S. J. Williams, T. C. Hamilton, and J. R. Testa, “The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel,” Cancer Research, vol. 60, no. 19, 5390 pages, 2000. View at Google Scholar
  20. D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, 307 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. S. Mabuchi, M. Ohmichi, Y. Nishio et al., “Inhibition of NF-κB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models,” Journal of Biological Chemistry, vol. 279, no. 22, 23477 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. V. Maldonado, J. Meléndez-Zajgla, and A. Ortega, “Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 381, no. 1, 67 pages, 1997. View at Publisher · View at Google Scholar
  23. A. Hoffmann, G. Natoli, and G. Ghosh, “Transcriptional regulation via the NF-κB signaling module,” Oncogene, vol. 25, no. 51, 6706 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. E. Burstein and C. S. Duckett, “Dying for NF-κB? Control of cell death by transcriptional regulation of the apoptotic machinery,” Current Opinion in Cell Biology, vol. 15, no. 6, 732 pages, 2003. View at Publisher · View at Google Scholar
  25. R. B. Marienfeld, L. Palkowitsch, and S. Ghosh, “Dimerization of the IκB kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF-κB activity,” Molecular and Cellular Biology, vol. 26, no. 24, 9209 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. M. A. Barry, C. A. Behnke, and A. Eastman, “Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia,” Biochemical Pharmacology, vol. 40, no. 10, 2353 pages, 1990. View at Publisher · View at Google Scholar
  27. A. Sodhi and R. A. K. Singh, “Mechanism of NF-κB translocation in macrophages treated in vitro with cisplatin,” Immunology Letters, vol. 63, no. 1, 9 pages, 1998. View at Publisher · View at Google Scholar
  28. H. Eichholtz-Wirth and D. Sagan, “IκB/NF-κB mediated cisplatin resistance in HeLa cells after low-dose γ-irradiation is associated with altered SODD expression,” Apoptosis, vol. 5, no. 3, 255 pages, 2000. View at Publisher · View at Google Scholar
  29. S.-E. Chuang, P.-Y. Yeh, Y.-S. Lu et al., “Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells,” Biochemical Pharmacology, vol. 63, no. 9, 1709 pages, 2002. View at Publisher · View at Google Scholar
  30. H. D. C. Francescato, R. S. Costa, C. Scavone, and T. M. Coimbra, “Parthenolide reduces cisplatin-induced renal damage,” Toxicology, vol. 230, no. 1, 64 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. J. S. Kim, J. M. Lee, Y.-J. Chwae et al., “Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways,” Biochemical Pharmacology, vol. 67, no. 8, 1459 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. A. A. Beg, W. C. Sha, R. T. Bronson, S. Ghosh, and D. Baltimore, “Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB,” Nature, vol. 376, no. 6536, 167 pages, 1995. View at Publisher · View at Google Scholar · View at PubMed
  33. P. J. Chiao, S. Miyamoto, and I. M. Verma, “Autoregulation of IκBα activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 1, 28 pages, 1994. View at Publisher · View at Google Scholar
  34. T. Kato, D. C. Duffey, F. G. Ondrey et al., “Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB,” Head & Neck, vol. 22, no. 8, 748 pages, 2000. View at Publisher · View at Google Scholar
  35. M. E. O'Brien, H. Anderson, E. Kaukel et al., “SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results,” Annals of Oncology, vol. 15, no. 6, 906 pages, 2004. View at Publisher · View at Google Scholar
  36. H.-Y. Ruan, M. Masuda, A. Ito et al., “Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines,” Head & Neck, vol. 28, no. 2, 158 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. K. Tozawa, T. Okamoto, Y. Hayashi, S. Sasaki, N. Kawai, and K. Kohri, “N-acetyl-L-cysteine enhances chemotherapeutic effect on prostate cancer cells,” Urological Research, vol. 30, no. 1, 53 pages, 2002. View at Publisher · View at Google Scholar
  38. M. M. M. Abdel-Latif, A. A. Raouf, K. Sabra, D. Kelleher, and J. V. Reynolds, “Vitamin C enhances chemosensitization of esophageal cancer cells in vitro,” Journal of Chemotherapy, vol. 17, no. 5, 539 pages, 2005. View at Google Scholar
  39. M. M. M. Abdel-Latif, J. M. O'Riordan, N. Ravi, D. Kelleher, and J. V. Reynolds, “Activated nuclear factor-κB and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy,” Diseases of the Esophagus, vol. 18, no. 4, 246 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. P. Y. Yeh, S.-E. Chuang, K.-H. Yeh, Y. C. Song, and A.-L. Cheng, “Involvement of nuclear transcription factor-κB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells,” Biochemical Pharmacology, vol. 66, no. 1, 25 pages, 2003. View at Publisher · View at Google Scholar
  41. H. Eichholtz-Wirth and K. Marx, “Clonal variability of radiation-induced cisplatin resistant HeLa cells,” Anticancer Research, vol. 18, 2989 pages, 1998. View at Google Scholar
  42. C. Aghajanian, “Clinical update: novel targets in gynecologic malignancies,” Seminars in Oncology, vol. 31, 22 pages, 2004. View at Publisher · View at Google Scholar
  43. C. T. Lee, J. Y. Seol, S. Y. Lee et al., “The effect of adenovirus-Iκ Bα transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II)(cisplatin) and doxorubicin(adriamycin),” Lung Cancer, vol. 41, no. 2, 199 pages, 2003. View at Publisher · View at Google Scholar
  44. I. Sánchez-Pérez and R. Perona, “Lack of c-Jun activity increases survival to cisplatin,” FEBS Letters, vol. 453, no. 1-2, 151 pages, 1999. View at Publisher · View at Google Scholar
  45. I. Sánchez-Pérez, S. A. Benitah, M. Martínez-Gomariz, J. C. Lacal, and R. Perona, “Cell stress and MEKK1-mediated c-Jun activation modulate NFκB activity and cell viability,” Molecular Biology of the Cell, vol. 13, no. 8, 2933 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  46. P. Y. Yeh, K.-H. Yeh, S.-E. Chuang, Y. C. Song, and A.-L. Cheng, “Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-κB activation by protein phosphatase 4-mediated NF-κB p65 Thr dephosphorylation,” Journal of Biological Chemistry, vol. 279, no. 25, 26143 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  47. H. L. Pahl, “Activators and target genes of Rel/NF-κB transcription factors,” Oncogene, vol. 18, no. 49, 6853 pages, 1999. View at Publisher · View at Google Scholar · View at PubMed
  48. J. K. Kim, K. D. Kim, E. Lee et al., “Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line,” Cancer Letters, vol. 212, no. 1, 61 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  49. J. K. Park, Y. M. Chung, S. Kang et al., “c-Myc exerts a protective function through ornithine decarboxylase against cellular insults,” Molecular Pharmacology, vol. 62, no. 6, 1400 pages, 2002. View at Publisher · View at Google Scholar
  50. J. Lokich and N. Anderson, “Carboplatin versus cisplatin in solid tumors: an analysis of the literature,” Annals of Oncology, vol. 9, no. 1, 13 pages, 1998. View at Publisher · View at Google Scholar
  51. S. Singh and M. K. Bhat, “Carboplatin induces apoptotic cell death through downregulation of constitutively active nuclear factor-κB in human HPV-18 E6-positive HEp-2 cells,” Biochemical and Biophysical Research Communications, vol. 318, no. 2, 346 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  52. K. D. Weaver, S. Yeyeodu, J. C. Cusack, Jr., A. S. Baldwin, Jr., and M. G. Ewend, “Potentiation of chemotherapeutic agents following antagonism of nuclear factor κB in human gliomas,” Journal of Neuro-Oncology, vol. 61, no. 3, 187 pages, 2003. View at Publisher · View at Google Scholar
  53. E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic, “Cellular and molecular pharmacology of oxaliplatin,” Molecular Cancer Therapeutics, vol. 1, no. 3, 227 pages, 2002. View at Google Scholar
  54. T. V. Rakitina, I. A. Vasilevskaya, and P. J. O'Dwyer, “Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κB signaling,” Cancer Research, vol. 63, no. 24, 8600 pages, 2003. View at Google Scholar
  55. E. Fokkema, H. J. M. Groen, M. N. Helder, E. G. E. de Vries, and C. Meijer, “JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin,” Biochemical Pharmacology, vol. 63, no. 11, 1989 pages, 2002. View at Publisher · View at Google Scholar
  56. J. M. Meerum Terwogt, G. Groenewegen, D. Pluim et al., “Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin,” Cancer Chemotherapy and Pharmacology, vol. 49, no. 3, 201 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  57. G. P. Stathopoulos, T. Boulikas, M. Vougiouka et al., “Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study,” Oncology Reports, vol. 13, no. 4, 589 pages, 2005. View at Google Scholar